Form 485BPOS LAZARD FUNDS INC
Securities Act File No. 33-40682
Investment Company Act File No. 811-06312
_____________________________________________________________________________________________
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM N-1A
| REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 | /X/ |
| Post-Effective Amendment No. 117 | /X/ |
| and | |
| REGISTRATION STATEMENT UNDER THE INVESTMENT COMPANY ACT OF 1940 | /X/ |
| Amendment No. 117 | /X/ |
(Check appropriate box or boxes)
THE LAZARD FUNDS, INC. |
| (Exact Name of Registrant as Specified in Charter) |
| (212) 632-6000 |
| (Registrant’s Telephone Number, including Area Code) |
| 30 Rockefeller Plaza, New York, New York 10112 |
| (Address of Principal Executive: Number, Street, City, State, Zip Code) |
Nathan A. Paul, Esq.
30 Rockefeller Plaza
New York, New York 10112
(Name and Address of Agent for Services)
Copy to:
Janna Manes, Esq.
Stroock & Stroock & Lavan LLP
180 Maiden Lane
New York, New York 10038-4982
It is proposed that this filing will become effective (check appropriate box)
| X | immediately upon filing pursuant to paragraph (b) | |
| on (DATE) pursuant to paragraph (b) | ||
| 60 days after filing pursuant to paragraph (a)(1) | ||
| on (DATE) pursuant to paragraph (a)(1) | ||
| 75 days after filing pursuant to paragraph (a)(2) | ||
| on (DATE) pursuant to paragraph (a)(2) of Rule 485. | ||
| If appropriate, check the following box: | ||
| this post-effective amendment designates a new effective date for a previously filed post-effective amendment. | ||
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933 and the Investment Company Act of 1940, the Registrant certifies that it meets all of the requirements for effectiveness of this Amendment to the Registration Statement under Rule 485(b) of the Securities Act of 1933 and has duly caused this Amendment to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, and State of New York, on the 19th day of January, 2017.
THE LAZARD FUNDS, INC.
By: /s/ Charles L. Carroll
Charles L. Carroll, Chief Executive Officer
Pursuant to the requirements of the Securities Act of 1933, this Amendment to Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.
|
/s/ Charles L. Carroll Charles L. Carroll |
President and Director | January 19, 2017 |
| /s/ Christopher Snively Christopher Snively |
Chief Financial Officer | January 19, 2017 |
|
/s/ Ashish Bhutani Ashish Bhutani |
Director | January 19, 2017 |
|
/s/ Franci J. Blassberg* Franci J. Blassberg |
Director | January 19, 2017 |
| /s/ Kenneth S. Davidson* Kenneth S. Davidson |
Director | January 19, 2017 |
|
/s/ Nancy A. Eckl* Nancy A. Eckl |
Director | January 19, 2017 |
|
/s/ Trevor W. Morrison* Trevor W. Morrison |
Director | January 19, 2017 |
|
/s/ Richard Reiss, Jr.* Richard Reiss, Jr. |
Director | January 19, 2017 |
| /s/ Robert M. Solmson* Robert M. Solmson |
Director | January 19, 2017 |
|
*By: /s/ Nathan A. Paul Attorney-in-fact, Nathan A. Paul |
||
EXHIBIT INDEX
| Exhibit No. | Description |
| EX-101.INS | XBRL Instance Document |
| EX-101.SCH | XBRL Taxonomy Extension Schema Document |
| EX-101.DEF | XBRL Taxonomy Extension Definition Linkbase |
| EX-101.LAB | XBRL Taxonomy Extension Labels Linkbase |
| EX-101.PRE | XBRL Taxonomy Extension Presentation Linkbase |
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Chiesi Group completes KalVista acquisition for $27 per share
- Lazard reports May assets under management at $284.8 billion
- Incyte to acquire Vega Therapeutics for $1.25 billion upfront
Create E-mail Alert Related Categories
SEC FilingsRelated Entities
LazardSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share